Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)

This study has been completed.
Sponsor:
Information provided by:
National Eye Institute (NEI)
ClinicalTrials.gov Identifier:
NCT00000142
First received: September 23, 1999
Last updated: September 16, 2009
Last verified: September 2009

September 23, 1999
September 16, 2009
April 1994
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00000142 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Not Provided

To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously known as HPMPC) for the treatment of retinitis.

CMV retinitis is the most common intraocular infection in patients with AIDS and is estimated to affect 35 percent to 40 percent of patients with AIDS. Untreated CMV retinitis is a progressive disorder, the end result of which is total retinal destruction and blindness. As of September 1997, drugs approved by the United States Food and Drug Administration (FDA) for the treatment of CMV retinitis were ganciclovir (Cytovene), foscarnet (Foscavir), and cidofovir (Vistide). Cidofovir has a prolonged duration of effect permitting intermittent administration. All systemically administered anti-CMV drugs are given in a similar fashion consisting of initial 2-week high-dose treatment (induction) to control the infection followed by long-term lower dose treatment (maintenance) to prevent relapse. Cidofovir is administered as an intravenous infusion once weekly for induction therapy and once every 2 weeks as maintenance therapy. The HPCRT evaluated the efficacy and safety of cidofovir therapy.

The HPCRT was a multicenter, randomized, controlled clinical trial of cidofovir for the treatment of CMV retinitis. Patients with small peripheral CMV retinitis lesions (i.e., not at risk of immediate loss of visual acuity) were randomized to immediate treatment with cidofovir or deferred therapy until the retinitis had progressed 750 ýým. Patients randomized to immediate therapy received either 1) low-dose cidofovir at 5 mg/kg once weekly induction for 2 weeks, followed by 3 mg/kg once every 2 weeks for maintenance or 2) high-dose cidofovir at 5 mg/kg once weekly induction for 2 weeks followed by 5 mg/kg once every 2 weeks for maintenance. Patients whose retinitis progressed were given treatment according to best medical judgement, and those assigned to deferral were generally treated with cidofovir.

Outcomes in this trial included retinitis progression, loss of retinal area, and morbidity.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Primary Purpose: Treatment
  • HIV Infections
  • Cytomegalovirus Retinitis
Drug: Cidofovir
Not Provided
Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med. 1997 Feb 15;126(4):264-74.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
February 1996
Not Provided

Patients were age 13 years or older with diagnoses of AIDS, according to current Centers for Disease Control and Prevention (CDC) definition, and small peripheral CMV retinitis. Retinitis lesion(s) must have been confined to less than 25 percent of the total area of the retina and confined to the periphery of the retina. Peripheral lesions were those located at least 1,500 um from the margin of the optic disc and 3,000 mm from the center of the fovea (entirely in zone 2 or 3). Patients must have had at least one lesion 750 um or greater in size that could be photographed and the ability to read three or more lines on ETDRS chart at 1 meter (Snellen equivalent of 8/200 or greater) in at least one eye diagnosed with CMV retinitis.

Both
13 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00000142
NEI-41
Not Provided
Not Provided
National Eye Institute (NEI)
Not Provided
Not Provided
National Eye Institute (NEI)
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP